Pulse Biosciences (PLSE) Expected to Post Quarterly Earnings on Thursday

Pulse Biosciences (NASDAQ:PLSE) is projected to announce its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of ($0.3095) per share and revenue of $0.52 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Pulse Biosciences (NASDAQ:PLSE) last announced its earnings results on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.07). Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%. The business had revenue of $0.43 million during the quarter, compared to analyst estimates of $0.53 million. On average, analysts expect Pulse Biosciences to post ($1.34) EPS for the current fiscal year and ($1.41) EPS for the next fiscal year.

Pulse Biosciences Trading Down 1.3%

Shares of PLSE opened at $52.20 on Wednesday. The stock has a fifty day moving average price of $51.19 and a two-hundred day moving average price of $31.67. Pulse Biosciences has a 52-week low of $12.56 and a 52-week high of $58.90.

Insider Activity

In other Pulse Biosciences news, COO Liane Teplitsky bought 1,001 shares of Pulse Biosciences stock in a transaction dated Tuesday, September 1st. The stock was bought at an average cost of $49.95 per share, for a total transaction of $49,999.95. Following the purchase, the chief operating officer owned 4,095 shares of the company’s stock, valued at $204,545.25. The trade was a 32.35% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders purchased 4,095 shares of company stock valued at $199,931 over the last ninety days. Company insiders own 74.00% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Oppenheimer increased their price objective on shares of Pulse Biosciences from $35.00 to $60.00 and gave the company an “outperform” rating in a report on Tuesday, October 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Thursday, October 15th. Needham & Company LLC began coverage on Pulse Biosciences in a report on Monday, August 17th. They set a “buy” rating and a $58.00 target price for the company. Wall Street Zen upgraded Pulse Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday, September 6th. Finally, Canaccord Genuity Group lifted their price objective on shares of Pulse Biosciences from $43.00 to $58.00 and gave the company a “buy” rating in a research report on Tuesday, October 6th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Pulse Biosciences currently has an average rating of “Moderate Buy” and an average price target of $60.20.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc (NASDAQ:PLSE) is a medical technology company developing bioelectric therapies based on its Nano-Pulse Stimulation (NPS) technology. The technology uses short, high-voltage electrical pulses to create temporary openings in cell membranes, with the goal of selectively affecting targeted cells while limiting thermal damage to surrounding tissue.

The company’s principal product is the CellFX System, a device designed to deliver NPS treatments for certain dermatologic conditions.